Urologic Oncology: Targeted Therapies & Biomarker Breakthroughs

Urologic oncology is accelerating through precision biomarkers, molecular diagnostics, and targeted therapies for prostate, bladder, renal, and testicular cancers. Genetic profiling helps clinicians identify tumor behavior, treatment responses, and resistance patterns. Immunotherapeutic agents, checkpoint inhibitors, antibody-drug conjugates, and precision radiotherapy improve survival outcomes with reduced toxicity. Liquid biopsies, circulating tumor DNA, and urinary biomarkers allow real-time disease monitoring and early relapse detection. Robotic-assisted surgery enables highly precise tumor removal while preserving organ function. Together, these advancements refine cancer care and support more personalized treatment pathways.

    Related Conference of Urologic Oncology: Targeted Therapies & Biomarker Breakthroughs

    December 10-11, 2025

    12th World Congress on Epidemiology & Public Health

    Amsterdam, Netherlands
    March 09-10, 2026

    17th Nephrology,Renal Medicine & Renal Care

    Dubai, UAE
    March 26-27, 2026

    22nd World Nephrology Conference

    Amsterdam, Netherlands
    April 27-28, 2026

    11th World Kidney Congress

    London, UK
    June 29-30, 2026

    18th World Nephrology Summit

    Aix-en-Provence, France

    Urologic Oncology: Targeted Therapies & Biomarker Breakthroughs Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in